A study that was published in recent weeks has given the world a sobering view of the number of cancer diagnoses that are ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...

The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

Background The epidemiology of native valve infective endocarditis (IE) has shifted toward older adults with substantial ...

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US ...

A fourth-year student from Mercy ­Secondary School Mounthawk in Co Kerry has won the 2026 Stripe Young Scientist and ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...